Miguel Vieira Martins, Doctoral Student at Máxima Butterfly, PhD Candidate/ Clinical Researcher at Princess Máxima Center for Pediatric Oncology, shared on LinkedIn:
“I am thrilled to share our latest research published in Pediatric Blood and Cancer, which explores the impact of blinatumomab on the immune recovery of infants with B-cell ALL.
While adding blinatumomab to standard chemotherapy has significantly improved outcomes for infants with KMT2A-rearranged acute lymphoblastic leukemia (ALL) – achieving an impressive 93.3% overall survival in our pilot study – it comes with a known challenge: immunoglobulin G (IgG) depletion.
Why this matters: Understanding these recovery patterns is crucial for developing better infection-prevention strategies and guiding IVIg supplementation.
We recommend that future trials continue to monitor immune reconstitution to further refine care for these high-risk infants.”
Title: Immunoglobulin Depletion and Recovery Following Blinatumomab in Infants With KMT2A-Rearranged ALL
Authors: Miguel Vieira Martins, Paola de Lorenzo, Rishi S. Kotecha, Andishe Attarbaschi, Gabriele Escherich, Karsten Nysom, Jan Stary, Alina Ferster, Benoit Brethon, Franco Locatelli, Martin Schrappe, Peggy E. Scholte-van Houtem, Maria G. Valsecchi, Rob Pieters, Inge M. van der Sluis
Other articles about acute lymphoblastic leukemia on OncoDaily.